Overview

• Cardiovascular biopharma's Q4 revenue rose yr/yr, driven by MYQORZO approvals

• Net loss for Q4 widened compared to last year

• Company holds $1.2 bln in cash, cash equivalents, and investments

Outlook

• Cytokinetics projects 2026 GAAP combined R&D and SG&A expenses of $830 mln to $870 mln

Result Drivers

• MYQORZO APPROVALS - Q4 revenue growth driven by MYQORZO approvals in U.S., China, and Europe, leading to milestone payments

• EXPENSE INCREASES - Higher R&D and G&A expenses due to clinical trials and commercial readiness efforts

Company press release: ID:nGNX4dSwwf

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Cytokinetics Inc is $88.00, about 28.9% above its February 23 closing price of $68.26

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.